PDF(Sci-hub)
Abstract：
BACKGROUND: China has achieved near-universal health coverage (UHC) for 95 percent of its population (>1.3 billion lives) as a result of healthcare reforms that began in 2009. However, one of many remaining issues in the Chinese healthcare system is the need to better optimize the allocation and use of healthcare resources in order to meet growing healthcare demands.
OBJECTIVE: The goals are to highlight the components of the China Guidelines for Pharmacoeconomic Evaluations (CGPE) 2020 Edition and discuss its future development for UHC in China.
METHODS: We review the development process of the CGPE 2020 edition, discuss the contemporary practice of the CGPE for UHC in China, describe new opportunities and challenges to the CGPE, and provide suggestions on the future development of the CGPE based on the current state of the healthcare system in China.
RESULTS: Pharmacoeconomics provides tools to evaluate the health returns and economic costs of pharmaceutical products in a scientific way for the optimal allocation of healthcare resources. Considering the great potential of pharmacoeconomics in China, demonstrated by its rapid development and recognition as a research field in the past decade, the standardization of pharmacoeconomic evaluations has become particularly important to improve the accuracy of evaluation results used for drug selection, price negotiations and adjustments.
CONCLUSIONS: Suggestions are made for the integration of CGPE into current framework of UHC in China, including standardizing the pharmacoeconomic evaluation process and updating CGPE on topics such as ethics and real-world research. The CGPE 2020 edition offers a standard to improve the quality of pharmacoeconomic evaluation research and enhance the value and efficiency of UHC in China.
OBJECTIVE: The goals are to highlight the components of the China Guidelines for Pharmacoeconomic Evaluations (CGPE) 2020 Edition and discuss its future development for UHC in China.
METHODS: We review the development process of the CGPE 2020 edition, discuss the contemporary practice of the CGPE for UHC in China, describe new opportunities and challenges to the CGPE, and provide suggestions on the future development of the CGPE based on the current state of the healthcare system in China.
RESULTS: Pharmacoeconomics provides tools to evaluate the health returns and economic costs of pharmaceutical products in a scientific way for the optimal allocation of healthcare resources. Considering the great potential of pharmacoeconomics in China, demonstrated by its rapid development and recognition as a research field in the past decade, the standardization of pharmacoeconomic evaluations has become particularly important to improve the accuracy of evaluation results used for drug selection, price negotiations and adjustments.
CONCLUSIONS: Suggestions are made for the integration of CGPE into current framework of UHC in China, including standardizing the pharmacoeconomic evaluation process and updating CGPE on topics such as ethics and real-world research. The CGPE 2020 edition offers a standard to improve the quality of pharmacoeconomic evaluation research and enhance the value and efficiency of UHC in China.
摘要：
背景：由于2009年开始的医疗改革，中国已经为其95％的人口（>13亿人的生命）实现了近乎全民健康覆盖（UHC）。然而,中国医疗体系中许多遗留问题之一是需要更好地优化医疗资源的分配和使用，以满足日益增长的医疗需求。
目的：目的是重点介绍2020年版《中国药物经济学评价指南》（CGPE）的组成部分，并讨论其在中国UHC的未来发展。
方法：我们回顾了CGPE2020版的开发过程，讨论中国UHCCGPE的当代实践，描述CGPE的新机遇和挑战，并根据中国医疗系统的现状，对CGPE的未来发展提出建议。
结果：药物经济学提供了以科学的方式评估药品的健康回报和经济成本的工具，以实现医疗保健资源的最佳分配。考虑到药物经济学在中国的巨大潜力，在过去十年中，它作为一个研究领域的快速发展和认可证明了这一点，药物经济学评价的规范化对于提高用于药物选择的评价结果的准确性尤为重要,价格谈判和调整。
结论：建议将CGPE整合到中国当前的UHC框架中，包括规范药物经济学评估过程和更新CGPE主题，如伦理和现实世界的研究。CGPE2020版提供了提高药物经济学评价研究质量、提升我国UHC价值和效率的标准。
目的：目的是重点介绍2020年版《中国药物经济学评价指南》（CGPE）的组成部分，并讨论其在中国UHC的未来发展。
方法：我们回顾了CGPE2020版的开发过程，讨论中国UHCCGPE的当代实践，描述CGPE的新机遇和挑战，并根据中国医疗系统的现状，对CGPE的未来发展提出建议。
结果：药物经济学提供了以科学的方式评估药品的健康回报和经济成本的工具，以实现医疗保健资源的最佳分配。考虑到药物经济学在中国的巨大潜力，在过去十年中，它作为一个研究领域的快速发展和认可证明了这一点，药物经济学评价的规范化对于提高用于药物选择的评价结果的准确性尤为重要,价格谈判和调整。
结论：建议将CGPE整合到中国当前的UHC框架中，包括规范药物经济学评估过程和更新CGPE主题，如伦理和现实世界的研究。CGPE2020版提供了提高药物经济学评价研究质量、提升我国UHC价值和效率的标准。
